Navigation Links
FDA Approves New Dosage Strength for INTELENCE®
Date:1/3/2011

TITUSVILLE, N.J., Jan. 3, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.  

The recommended oral dose of INTELENCE tablets is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. The new 200 mg product formulation is expected to launch in the U.S. later this month, and the 100 mg tablet will remain available. Patients who are unable to swallow INTELENCE tablets whole may disperse the tablets in a glass of water.

The FDA granted accelerated approval to INTELENCE in January 2008, and it has since been approved in more than 65 countries. INTELENCE received traditional FDA approval in November 2009, based on 48-week data from the DUET-1 and DUET-2 studies, and is currently marketed in the U.S. by Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P.

INTELENCE IndicationINTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in ARV treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 48 analyses from two randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class ARV (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

  • Treatment history and, when available, resistance testing, should guide the use of INTELENCE.
  • The use of other active ARV agents with INTELENCE is associated with an increased likelihood of treat
    '/>"/>

  • SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... Insulet Corporation (NASDAQ: PODD ), the ... ® Insulin Management System, today announced preliminary revenue ... The Company also announced that it will postpone the ... conference call from Thursday, July 30, as originally scheduled. ... , Preliminary second quarter revenue ...
    (Date:7/29/2015)... 2015  UBM Canon brings MEDevice San Diego Conference ... Marina on September 1-2, 2015, with a multi-track conference ... the Business Development track will be a panel on ... Investors, featuring Renee Ryan , Vice President of ... Ahrens , Partner, Canaan Partners; and Jordan Kramer ...
    (Date:7/29/2015)... 2015  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
    Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
    (Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, ... surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned ... many patients from around the world. , “Like treatment of any other disease or ...
    (Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) ... National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of 69 ...
    (Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial and ... from the AC units and ventilation systems on hospital roofs. Bird droppings can carry ... virus. When these droppings dry, the fine powder can be carried into hospitals via ...
    (Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
    (Date:7/30/2015)... ... 30, 2015 , ... After a three year trial designed to study the ... as the “bionic eye,” researchers have determined the trial to be a success, and ... or already affected by complete vision loss as a result of Retinitis pigmentosa. The ...
    Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
    ... (April 19, 2010) -- The University of South Florida (USF) ... health records, with the support of a $5.9 million ... last week. "The University of South Florida is the ... and now is one of just a handful of universities ...
    ... ... the MTA,s zero-tolerance policy on the usage of cell phones despite this driver,s violent disagreement ... New ... being told by a supervisor that he should not talk on the phone while driving. ...
    ... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
    ... activity in the brain can affect language development in ... more frequently on children with severe language impairment to ... reveals a thesis from the Sahlgrenska Academy at the ... children of varying ages, divided into groups. The first ...
    ... smoke-free settings, but doctors have concerns, , MONDAY, April ... Reynolds launched Camel Orbs, dissolvable nicotine pellets flavored with ... smokers who find themselves in smoke-free surroundings. , But ... Pediatrics warn that the product, which can ...
    ... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
    Cached Medicine News:Health News:PaperFree Florida to help move physicians towards electronic health records 2Health News:PaperFree Florida to help move physicians towards electronic health records 3Health News:David Perecman Comments On Bus Driver Assaulting Supervisor In New York 2Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:Language dysfunction in children may be due to epileptic brain activity 2Health News:Kids Could Overdose From Nicotine-Laced 'Candy' 2Health News:UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis 2
    ... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
    ... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
    Inquire...
    ... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
    Medicine Products: